Knowledge Hub · Saxsons Lead Vial Shield
The HVL in lead climbs roughly six-fold from Tc-99m at 140 keV to F-18 / Ga-68 at 511 keV. A vial-shield family that covers the whole NM activity spectrum has to ladder accordingly — and an in-between 12 mm tier for I-131 therapy work. This page is why each tier exists, what each isotope picks, and how the AERB extremity-dose framework reads off the per-batch certificate pack.
Why this matters
Lead HVL ladder
The half-value layer (HVL) in lead at the relevant NM photopeak energies climbs roughly six-fold from SPECT to PET: ~0.27 mm at 140 keV (Tc-99m), ~3 mm at 364 keV (I-131), and ~4.1 mm at 511 keV (F-18 / Ga-68 / Lu-177 annihilation contribution). The shielding tier that gives > 99 % attenuation at one energy is dramatically inadequate at the next. A vial-shield family that covers the whole NM activity spectrum needs to ladder from 6 mm Pb for routine Tc-99m up to 30 mm for routine PET and 50 mm for high-activity PET / Lu-177 — and an in-between 12 mm tier for I-131 therapy work. Picking a single "good enough" thickness for everything either over-shields the routine workflow (chassis weight) or under-shields the high-activity workflow (extremity dose).
Based on: NIST XCOM photon-attenuation cross-section database; NCRP Report 49 / Report 147 — Structural Shielding for Medical Use Facilities.
Read source ↗6 mm at the Tc-99m K-edge
Tc-99m at 140 keV sits just above the lead K-edge at 88 keV, exactly where lead's photoelectric absorption is at its strongest. 6 mm of Pb at 140 keV is approximately 22 half-value layers — over six orders of magnitude attenuation. That looks dramatically over-built for a single photopeak. The reason it is the routine tier: at the dose-rate from a typical kit vial, even the residual transmitted gamma at 22 HVL is the dose-rate that matters across an 8-hour shift across 30 dispenses. The over-built tier is the one that keeps the cumulative extremity dose comfortably inside the AERB 500 mSv annual budget.
Based on: NIST XCOM lead photon-attenuation data; AERB Safety Code for Nuclear Medicine Facility extremity-dose framework.
Read source ↗I-131 needs the step-up
At 364 keV — the I-131 primary photopeak — the half-value layer in lead is roughly 3 mm. The SPECT 6 mm tier is only ~2 HVL at I-131; transmission ~25 %. For an I-131 therapy capsule decant at GBq-level activity, that transmission rate fails to bring the dose-rate at the operator's fingers below the AERB action threshold. The 12 mm Pb tier delivers ~4 HVL at 364 keV — transmission ~6 %, which is the working envelope for routine I-131 therapy work. Departments that try to dispense I-131 using only their SPECT shields end up with extremity-dose log entries that drive the radiation safety officer to escalate.
Based on: NIST XCOM lead attenuation at 364 keV; AAPM Report 88 — Quality assurance for radiopharmacy.
Read source ↗PET requires 30 mm minimum
At 511 keV (the F-18 / Ga-68 / Cu-64 annihilation peak), the half-value layer in lead is roughly 4.1 mm. The 30 mm Pb tier delivers ~7 HVL — transmission ~0.8 %. The 50 mm tier brings that to ~12 HVL — transmission ~0.025 %. The reason the high-activity PET tier exists: the per-shift dispense activity in a busy PET radiopharmacy (30+ FDG doses, each at 350–550 MBq) compounds the per-dispense exposure. Even with the routine 30 mm tier, the cumulative extremity dose from the source vial across the shift is the dominant contributor; the 50 mm tier brings that down further for high-throughput sites and source-vial work.
Based on: NIST XCOM lead attenuation at 511 keV; AAPM Report 108 — PET-CT acceptance testing and QA; ICRP 103 extremity-dose limit.
Read source ↗Magnetic top-cap ergonomics
A magnetic top cap on the needle hole gives one-touch open / close. The faster cycle time is real — ~1 second per dispense vs ~5 seconds for a screw-cap on a busy 30-dispense PET shift compounds to several minutes saved across the day. The larger benefit is what does NOT happen: with a magnetic cap the operator never fully removes the cap, never carries it separately on the bench, never has the moment of "where did I put the cap" mid-dispense. The cap stays on the shield, the operator works through the magnetic interface, the per-dispense exposure stays at the shielded surface. The screw-cap design forces the operator to put the cap somewhere — and that somewhere is usually less shielded than the source vial.
Based on: AAPM Report 88 — Quality assurance for radiopharmacy; clinical dispensing-line ergonomics literature.
Read source ↗β/γ Perspex inner layer
Y-90 is essentially pure β-emitter (E_max 2.28 MeV); Lu-177 is β-emitter with a small γ branching (113 / 208 keV). Putting raw lead in the β path generates bremsstrahlung — the β electrons decelerating in the Pb produce secondary gamma photons across a broad spectrum. The secondary γ then transmits through the Pb at the lead attenuation rate. A Perspex (PMMA) or acrylic inner layer absorbs the β BEFORE it reaches the lead — eliminating the bremsstrahlung source. The outer Pb layer then handles the primary γ (Lu-177) and the residual radiation. The hybrid 6 mm Pb + 6 mm Perspex shield delivers a lower transmitted dose-rate than 12 mm Pb alone for Y-90 / Lu-177 work, while staying in the same chassis weight envelope.
Based on: NCRP Report 49 bremsstrahlung-shielding guidance; AAPM Report 88 hybrid-shielding for β-emitters.
Read source ↗AERB, ICRP, NIST, NCRP and AAPM documents that anchor lead vial-shield selection.
Indian regulatory framework for nuclear-medicine facility licensing including hot-lab shielding and extremity-dose-monitoring expectations.
Current ICRP framework defining the 500 mSv/year occupational extremity-dose limit referenced by the AERB dose-monitoring programme.
Authoritative reference for lead photon-attenuation coefficients at 140 keV (Tc-99m), 364 keV (I-131), 511 keV (F-18 / Ga-68) and other NM energies.
NCRP shielding-design framework covering lead-attenuation half-value layers used to size shielding to per-isotope workflow.
AAPM framework for radiopharmacy QC including shielded-dispensing equipment expectations and bremsstrahlung-shielding for β-emitters.
Where next